宜宾仪器祛斑宜宾内双割双眼皮多久恢复,宜宾眼部除皱的方法,宜宾去鱼尾纹眼袋抬头纹,宜宾专业吸脂隆胸医院,宜宾韩式双眼皮恢复期,宜宾专业隆鼻尖手术,宜宾割双眼皮割眼角多少钱

The United States Secret Service said on Monday that following an investigation that closed several streets near the White House due to a suspicious package left in the area of Pennsylvania Avenue and Lafayette Park, the package was deemed "safe."The Secret Service said at 5:40 p.m. ET that H Street NW between 15th and 17th, Pennsylvania Ave between 15th and 17th, and the White house North Fence Line are closed.By 6:10 p.m., the Secret Service allowed streets near the White House to reopen after deeming the package as safe. 592

The stock market is on the comeback trail.After another wobbly session, the Dow soared 287 points, or 1.2%, on Friday. It was the index's best day since August.The Dow had soared 400 points at the open before giving up most of those gains and then resuming its rally. The Dow lost 1,378 points over Wednesday and Thursday.The broader S&P 500 jumped 1.4% on Friday. The Nasdaq, which has taken the brunt of the recent stock market turbulence, spiked 2.3%.Despite Friday's rebound, all three major indexes suffered their worst weeks since March. And the S&P 500 is down three straight weeks. That hasn't happened since the Brexit referendum of June 2016.Investing experts weren't exactly sure what turned stocks negative by midday. The driving forces behind this week's downturn -- trade war and interest rate fears -- were around before this week, and yet market volatility is spiking."The sellers have control right now," said Justin Walters, co-founder of Bespoke Investment Group. "The scariest sell-offs are the ones you can't tie to a specific reason."Stocks had turned sharply south over the past week because investors are concerned about rising interest rates. As the Federal Reserve raises rates to keep the economy from overheating, investors have been getting out of bonds, driving down their price and driving up their yields. Suddenly, the return on bonds has become competitive with some stocks — particularly risky tech stocks.Rising interest rates also increase borrowing costs for households and businesses, eating into corporate profits."What we are seeing now is changing sands. The ground isn't stable and people are figuring out where to go next," said JJ Kinahan, chief market strategist with TD Ameritrade.Tech stocks have come under fire because they are some of the riskiest and most expensive parts of the market. Investors fear that tech companies may not hold up well in a downturn, particularly as interest rates spike. A proxy for the tech sector had its sharpest plunge in seven years on Wednesday.But Big Tech on Friday regained some of its losses. Facebook (FB), Apple (AAPL), Amazon (AMZN), Netflix (NFLX) and Google (GOOGL) were all up.Asian and European markets also came back Friday. The Hang Seng soared 2.2%. Stocks in Shanghai rose 0.9% and the Nikkei rose 0.5%. Stocks in London, Germany and France all rose about a half percentage point.Markets had bounced back Friday morning following news that President Donald Trump plans to meet next month with Chinese leader Xi Jinping at the G-20 summit. That eased some of the investors' fears about another trade war escalation. China also reported its exports rose nearly 15% in September, stronger than expected. That suggests China is weathering the first waves of new tariffs that the Trump administration imposed on billion of Chinese exports this summer.But Kinahan is still worried about US-China trade talks. He thinks that a deal is key in order for the markets to get back on track, adding that a full-blown trade war could undo much of the positives from the Trump administration's pro-business policies."The concern is that if nobody blinks, it could negate all the tax cuts we had," he said.Earnings season also kicked off Friday morning, with JPMorgan (JPM) and Citigroup (C) reporting their quarterly finances before the bell. Wall Street analysts expected the financial sector to post another incredibly profitable quarter — and JPMorgan managed to?beat their already lofty expectations.In times of market turbulence, there's nothing like soaring profits to calm investors' nerves.Rebounds after disastrous market selloffs are common. Investors who think the market may be oversold look to buy stocks they think are suddenly cheap.But markets are fickle. 3804

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

The Santa Ana Zoo is providing shelter for about 150 animals from Orange County Zoo in Irvine Regional Park that were evacuated on Oct. 26 because of the Silverado and Blue Ridge wildfires. #CityofSantaAna @SantaAnaZoo @SantaAnaParks #silveradocanyonfire #BlueRidgeFire pic.twitter.com/qb0ZDQ83ck— City of Santa Ana (@CityofSantaAna) October 27, 2020 358

The Twitter account that once belonged to former Republican presidential candidate Herman Cain tweeted Sunday evening that new CDC info indicated that COVID-19 "isn't as deadly" as once thought — despite the fact that Cain himself died of the virus just weeks ago.Cain died of COVID-19 on July 30 — four weeks after his office announced that he had been hospitalized in connection with the disease.On Aug. 11, Cain's daughter said in an update on his website that his family and campaign staff would continue to post content on the web and operate under the moniker "The Cain Gang.""He would have wanted us to do this. And that's exactly what we're going to do," Cain's daughter, Dr. Melanie Cain Gallo, wrote on HermanCain.com.In the weeks since the announcement, Cain's Twitter account has actively been sharing news links from largely conservative-leaning news outlets. On Sunday evening, the account tweeted a link to a story about a recent CDC announcement stating that COVID-19 was only listed as the sole cause of death for 6% of those killed by the virus."It looks like the virus is not as deadly as the mainstream media first made it out to be," the "Cain Gang" wrote on Twitter. 1196